

FACT SHEET

MANULIFE DANA EKUITAS TEKNOLOGI KESEHATAN GLOBAL DOLAR

OCT 2021

Investment Objective

To achieve long term capital growth by investing mainly in equity securities of companies which predominant economic activities are in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology sectors, onshore and/or offshore, directly and/or through mutual fund(s).

Fund Information

 Fund Currency
 :
 USD

 Type of fund
 :
 Equity

 Valuation
 :
 Daily

Custodian Bank : Bank DBS Indonesia

Annual Management Fee : 2.50%

Net Asset Value/Unit ³⁾ : USD 1.0211

Bloomberg Code : MATKGMU IJ


Performance Since Inception



Monthly Performance Last 3 Years



Risk Classification



Top 5 Holdings

1 BlackRock World Healthsience Fund D2 USD

Fund Performance

Performance in USD per (29/10/21)								
	1 mo	3 mo	6 mo	YTD	1 yr	3 yr ¹⁾	5 yr ¹⁾	Since Inception 1)
MANTKG	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2.11%
BM ²⁾	n/a	n/a	n/a	n/a	n/a	n/a	n/a	4.17%
Yearly Performance								
	2020	2019	2018	2017	2016	2015	2014	2013
MANTKG	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
BM ²⁾	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a

Note

- 1) Annualized (1 year = 365 days) and using compound method (for products that have been more than one year old since inception).
- 2) The benchmark is MSCI World Health Care Index.
- 3) The Net Asset Value / Unit has calculated the costs, including fees related to transaction and transaction settlement as well as administration and recording.

Investment Manager Commentary

Global healthcare equity sektor posted positive performance in October, despite of concerns of inflation and global supply chain disruption. US inflation rose to 5.4% in September as supply has difficulties catching up with rising demand amid supply chain disruption. The Fed views rising inflation as temporary and inflation will moderate once supply chain issue improves. The Fed also signals that tapering is likely to begin in November. Meanwhile the market turned more positive as Q3 earnings report was above market expectation, overshadowing concern of supply chain disruption to the economy. Over the long-term, secular drivers for the sector remain in place; firstly, aging demographics in both developed and developing countries and secondly, innovation in medical technology. The combination of these secular trends, with favourable valuation creates an attractive long-term investment opportunity.

Disclaimer: This report is prepared by PT Asuransi Jiwa Manulife Indonesia only for information purposes and not to be used as a sales offering or proposal. Although this report has been prepared meticulously, PT Asuransi Jiwa Manulife Indonesia does not guarantee its accuracy, sufficiency or completeness, and is not responsible for any consequences arising from any actions which are based on the information stated herein. Investments in capital market instruments are subject to various risks which include, but not limited to, market risk, credit risk, interest rate risk, exchange rate risk (particularly in Fund which has allocation in offshore investment instruments in different currencies than the Fund's currency), liquidity risk and other risks which could result in performance volatility. Therefore, the performance of this Fund is not guaranteed, the unit price of each Fund may go up or down and past performance does not necessarily indicative of future performance.

Manulife Indonesia

Established in 1985, PT Asuransi Jiwa Manulife Indonesia (Manulife Indonesia) is part of Manulife Financial Corporation Group, a Canadian financial services group that operates in Asia, Canada and the United States. Manulife Indonesia offers a wide range of financial services, including life insurance, accident and health insurance, investment and pension plans to individual customers and group clients in Indonesia. Through a network of almost 11,000 employees and professional agents spread across more than 25 sales offices, Manulife Indonesia serves more than 2 million customers in Indonesia.

PT Asuransi Jiwa Manulife Indonesia is registered and supervised by the Otoritas Jasa Keuangan (OJK). To learn more about Manulife Indonesia, follow us on Facebook, Twitter, Instagram, YouTube, or visit









